23andMe customers notified of bankruptcy and potential claims — deadline to file is July 14
23andMe, a prominent genetic testing company, is undergoing Chapter 11 bankruptcy, affecting millions of customers who may file claims during its restructuring.
MAIN POINTS
- 23andMe is a well-known genetic testing company.
- The company is currently navigating Chapter 11 bankruptcy.
- Millions of current and former customers are notified about potential claims.
- Subsidiaries like Lemonaid Health and LPRXOne are also involved in the bankruptcy.
TAKEAWAYS
- Customers may be eligible to file claims during the restructuring process.
- The bankruptcy affects 23andMe and 11 of its subsidiaries.
- The company's financial struggles have led to significant restructuring efforts.
- The situation highlights challenges faced by once high-valued tech companies.